Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is a promising late-stage biopharmaceutical company with a positive outlook on its stock. The potential of its lead drug candidate, cadisegliatin, in treating type 1 and type 2 diabetes, along with its projected peak sales of $650M and its exploration of partnerships for commercialization, make it a strong investment opportunity. Additionally, the experience and backgrounds of the company's CEO and CFO add credibility to its success potential.

Bears say

vTv Therapeutics is facing several challenges, including its dependence on one main drug candidate, CATT1, for potential revenue, and the need for additional trials beyond CATT1 for FDA approval. Its real-world adoption may also be limited due to competition and regulatory scrutiny for oral adjunctive therapies. Additionally, the company has faced issues with clinical holds and potential intellectual property risks, which could impact its future success. All of these factors contribute to a negative outlook for vTv Therapeutics from a financial analyst's perspective.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.